MARKET

EYES

EYES

Second Sight Med Prods Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
+0.060
+2.64%
After Hours: 2.340 +0.01 +0.43% 18:36 06/24 EDT
OPEN
2.310
PREV CLOSE
2.270
HIGH
2.340
LOW
2.270
VOLUME
136.07K
TURNOVER
0
52 WEEK HIGH
5.40
52 WEEK LOW
1.140
MARKET CAP
91.82M
P/E (TTM)
-10.0388
1D
5D
1M
3M
1Y
5Y
3 Stocks Under $3 Insiders Are Aggressively Buying
The Federal Open Market Committee opted to raise fed funds rates by 0.75% on Wednesday to a new target range of between 1.5% and 1.75%. Investors, meanwhile, focused on some notable insider trades.
Benzinga · 06/16 12:12
Insiders Buy Around $2M Of 2 Penny Stocks
US stock futures traded higher on Thursday, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades.
Benzinga · 05/26 12:04
Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®
LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano...
Business Wire · 04/14 12:00
Haemonetics, Second Sight top healthcare gainers; Pulse, Karyopharm lead losers
Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Thera...
Seekingalpha · 02/08 15:01
Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical
Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc 
Benzinga · 02/08 11:33
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal
MT Newswires · 02/08 05:58
BRIEF-Second Sight Medical Products And Nano Precision Medical Announce Merger Agreement
reuters.com · 02/07 21:55
Second Sight Medical Products to acquire Nano Precision Medical in all-stock deal
Second Sight Medical Products (NASDAQ:EYES) will acquire Nano Precision Medical (NPM) and merge it with a wholly-owned subsidiary in an all-stock transaction. EYES will issue ~134M shares to acquire NPM.
Seekingalpha · 02/07 21:53
More
No Data
Learn about the latest financial forecast of EYES. Analyze the recent business situations of Second Sight Med Prods Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
High2.500
Average2.500
Low2.500
Current 2.330
EPS
Actual
Estimate
-0.10-0.07-0.05-0.02
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 57
Institutional Holdings: 3.68M
% Owned: 9.33%
Shares Outstanding: 39.41M
TypeInstitutionsShares
Increased
7
69.91K
New
6
209.83K
Decreased
8
540.23K
Sold Out
8
580.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.57%
Healthcare Equipment & Supplies
+2.14%
Key Executives
Non-Executive Chairman/Independent Director
Gregg Williams
Chief Executive Officer
Scott Dunbar
Chief Executive Officer
Edward Sedo
Chief Operating Officer
Edward Randolph
Vice President
Jessy Dorn
Independent Director
Dean Baker
Independent Director
Alexandra Larson
Independent Director
Jonathan McGuire
Independent Director
Aaron Mendelsohn
Independent Director
Matthew Pfeffer
No Data
No Data
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.